PTC
18.10.2018 12:02:07 CEST | Business Wire | Press release
PTC (NASDAQ: PTC) today announced from Augmented World Expo (AWE) Europe 2018 the availability of new research in conjunction with Aberdeen Group titled, “How the Best-in-Class Use Augmented Reality for Superior Service Management.” The comprehensive research study and corresponding report identifies significant financial improvements realized by industrial companies embracing augmented reality (AR), and provides best practices for unlocking the potential of the technology across various environments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181018005051/en/
In addition to the report published today, PTC announced exclusive data from Aberdeen that shows that organizations using AR have experienced significant year-over-year business growth and have improved their bottom lines dramatically.
“The rapid pace of the global market, digital transformation, and increasing shortage of highly skilled workers have produced a disruptive threat for businesses,” said Tom Paquin, research analyst, Aberdeen Group. “However, as evidenced by our latest report with PTC, companies that invest in AR, particularly manufacturing and service organizations, have the opportunity to gain a competitive advantage.”
For enterprises, AR can empower workers to understand and interact with the physical and digital worlds, build new skills with reduced training time and cost, and make informed decisions faster. As a result, businesses can unlock increased productivity and improve the effectiveness of training, manufacturing, and service.
“AR is one of the fastest growing segments in the technology market and has been shown to create significant business value for organizations adopting it. Industrial enterprises are keen to improve customer experiences, open up new revenue streams, and disrupt competition by leveraging the new AR capabilities for product and service differentiation,” said Jim Heppelmann, president and CEO, PTC. “Use cases being developed for end customers have a strong focus on service or maintenance instructions, enabling them to reduce machine downtime and maximize product value.”
AWE Europe 2018
PTC and the topic of enterprise AR took
center stage today at AWE Europe 2018, the world’s leading AR and VR
conference and expo, held October 18-19 in Munich, Germany.
This morning, Mike Campbell, EVP, Augmented Reality Products, PTC, led a keynote session titled, “PTC Vision for Augmented Reality in the Enterprise ,” in which he spoke about the state of AR in the industrial enterprise, reviewed customer use cases, and illustrated the power of AR to fundamentally change the way people work and to allow organizations to re-imagine how to manufacture, sell, operate, and service industrial products.
“Augmented reality can deliver a significant advantage for industrial organizations as part of their overall digital transformation,” said Mr. Campbell. “PTC customers are better leveraging existing investments in CAD, IoT, and digitalization of content through AR experiences, enabling people to visualize and interact with the digital world in the real-time context of their daily work.”
As a Titanium Sponsor of and exhibitor at the event, PTC is showcasing its latest AR solutions – Vuforia Studio, Vuforia Engine, and Vuforia Chalk – as well as distributing copies of the Aberdeen research report at booth 118. PTC is also participating in The International Symposium on Mixed and Augmented Reality (ISMAR) , which runs in conjunction with AWE Europe, in booth 405.
Adoption Under the Vuforia Brand
In line with the data and
findings of the Aberdeen report, PTC has experienced substantial growth
and adoption across its dedicated AR business unit. Over 60,000
commercial AR apps have been deployed with PTC’s Vuforia®
Engine. In addition, more than 14,000 participants have joined PTC’s
Vuforia Studio Free Trial program
, providing valuable feedback on
use case priorities and hardware requirements, and over 550,000
registered developers use Vuforia as their preferred platform to create
AR apps.
PTC has leveraged Vuforia to expand the capabilities of its market-leading ThingWorx ® Industrial Innovation Platform, enabling customers to visualize, instruct, guide, and improve interactions with physical things. Aberdeen data released today shows that Internet of Things (IoT) technology is currently a function of 82 percent of all businesses leveraging AR.
Aberdeen Report: “How the Best-in-Class Use Augmented Reality for
Superior Service Management”
The Aberdeen report, which
investigates service AR use cases of best-in-class organizations versus
all other adopters, offers the following highlights:
- Service organizations using AR have performed significantly better than non-users across customer retention, customer satisfaction, and year-over-year revenue improvement
- The best-in-class companies have performed, on average, 25 percent better than their peers across performance measurements, including regulatory and SLA compliance
- 34 percent of best-in-class organizations leverage AR-powered training, 31 percent use on-site guides, and 25 percent are using AR-powered knowledge sharing
To download a copy of the full report, please visit https://www.ptc.com/en/AWE-Europe .
Additional Resources
- Download the Aberdeen Report
- PTC Augmented Reality
- The State of Industrial Augmented Reality
- Harvard Business Review: “Why Every Organization Needs an AR Strategy,” authored by PTC CEO Jim Heppelmann and Harvard Professor Michael Porter
The adoption by customers of Vuforia AR solutions to date is not indicative of the amount of revenue with respect to any particular period or that customers will continue to adopt or deploy such technologies at any particular rate.
About PTC (NASDAQ: PTC)
PTC helps companies around the world
reinvent the way they design, manufacture, operate, and service products
in and for a smart, connected world. In 1986 we revolutionized digital
3D design, and in 1998 were first to market with Internet-based product
lifecycle management. Today, our leading industrial innovation platform
and field-proven solutions enable you to unlock value at the convergence
of the physical and digital worlds. With PTC, manufacturers and an
ecosystem of partners and developers can capitalize on the promise of
the Internet of Things and augmented reality technology today and drive
the future of innovation.
PTC, Vuforia, ThingWorx, and the PTC logo are trademarks or registered trademarks of PTC Inc. and/or its subsidiaries in the United States and other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181018005051/en/
Contact:
PTC Jack McAvoy, 781-370-6143 Corporate Communications jmcavoy@ptc.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
